These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36462619)

  • 1. Magnetic Resonance-Guided Adaptive Radiation Therapy for Prostate Cancer: The First Results from the MOMENTUM study-An International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiation Therapy.
    Teunissen FR; Willigenburg T; Tree AC; Hall WA; Choi SL; Choudhury A; Christodouleas JP; de Boer JCJ; de Groot-van Breugel EN; Kerkmeijer LGW; Pos FJ; Schytte T; Vesprini D; Verkooijen HM; van der Voort van Zyp JRN
    Pract Radiat Oncol; 2023; 13(3):e261-e269. PubMed ID: 36462619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
    Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI-Guided Ultrafocal HDR Brachytherapy for Localized Prostate Cancer: Median 4-Year Results of a feasibility study.
    Peters M; van Son MJ; Moerland MA; Kerkmeijer LGW; Eppinga WSC; Meijer RP; Lagendijk JJW; Shah TT; Ahmed HU; van der Voort van Zijp JRN
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1045-1053. PubMed ID: 30926575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer.
    Bryant C; Smith TL; Henderson RH; Hoppe BS; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Su Z; Li Z; Lee D; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):422-434. PubMed ID: 27084658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes of Prostate SBRT Using Non-adaptive MR-Guided Radiotherapy.
    Sandoval ML; Rishi A; Latifi K; Grass GD; Torres-Roca J; Rosenberg SA; Yamoah K; Johnstone PAS
    Cancer Control; 2024; 31():10732748241270595. PubMed ID: 39206515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Image guided hypofractionated radiotherapy and quality of life for localized prostate cancer: prospective longitudinal study in 337 patients.
    Jereczek-Fossa BA; Santoro L; Zerini D; Fodor C; Vischioni B; Dispinzieri M; Bossi-Zanetti I; Gherardi F; Bonora M; Caputo M; Vavassori A; Cambria R; Garibaldi C; Cattani F; Matei DV; Musi G; De Cobelli O; Orecchia R
    J Urol; 2013 Jun; 189(6):2099-103. PubMed ID: 23313200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment.
    Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
    Radiat Oncol; 2020 Mar; 15(1):69. PubMed ID: 32248826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-Dose-Rate Brachytherapy Combined With Ultrahypofractionated Radiation Therapy for Clinically Localized, Intermediate-Risk Prostate Cancer: Results From a Prospective Trial.
    Kollmeier MA; McBride S; Varghese M; Debonis D; Zhang Z; Cohen G; Damato AL; Mychalczak B; Gewanter R; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):905-913. PubMed ID: 32505609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.
    Zapatero A; Roch M; Castro Tejero P; Büchser D; Martin de Vidales C; González S; Rodríguez P; San Jose LA; Celada G; Murillo MT
    Br J Radiol; 2022 Mar; 95(1131):20210683. PubMed ID: 34538073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study.
    Tetar SU; Bruynzeel AME; Oei SS; Senan S; Fraikin T; Slotman BJ; Moorselaar RJAV; Lagerwaard FJ
    Eur Urol Oncol; 2021 Aug; 4(4):628-634. PubMed ID: 32536573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
    Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
    BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer.
    Vargas CE; Alam NB; Terk M; Niska JR; Cesaretti J; Swartz D; Vashi A; Kasraeian A; West CS; Blasser M; Moore C
    Cancer Treat Res Commun; 2019; 19():100119. PubMed ID: 30772671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reporting combined outcomes with Trifecta and survival, continence, and potency (SCP) classification in 337 patients with prostate cancer treated with image-guided hypofractionated radiotherapy.
    Jereczek-Fossa BA; Zerini D; Fodor C; Santoro L; Maucieri A; Gerardi MA; Vischioni B; Cambria R; Garibaldi C; Cattani F; Vavassori A; Matei DV; Musi G; De Cobelli O; Orecchia R
    BJU Int; 2014 Dec; 114(6b):E3-E10. PubMed ID: 24712723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurovascular-Sparing MR-Guided Adaptive Radiotherapy in Prostate Cancer; Defining the Potential Population for Erectile Function-Sparing Treatment.
    Teunissen FR; van der Voort van Zyp JRN; Verkooijen HM; Wortel RC
    J Sex Med; 2022 Jul; 19(7):1196-1200. PubMed ID: 35618631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter
    Fink CA; Ristau J; Buchele C; Klüter S; Liermann J; Hoegen-Saßmannshausen P; Sandrini E; Lentz-Hommertgen A; Baumann L; Andratschke N; Baumgartl M; Li M; Reiner M; Corradini S; Hörner-Rieber J; Bonekamp D; Schlemmer HP; Belka C; Guckenberger M; Debus J; Koerber SA
    Clin Transl Radiat Oncol; 2024 May; 46():100771. PubMed ID: 38586081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study.
    Sritharan K; Daamen L; Pathmanathan A; Schytte T; Pos F; Choudhury A; van der Voort van Zyp JRN; Kerkmeijer LGW; Hall W; Hall E; Verkooijen HM; Herbert T; Hafeez S; Mitchell A; Tree AC
    Clin Transl Radiat Oncol; 2024 May; 46():100742. PubMed ID: 38440792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Online Adaptive MR-Guided Ultrahypofractionated Radiotherapy of Prostate Cancer on a 1.5 T MR-Linac: Clinical Experience and Prospective Evaluation.
    Potkrajcic V; Gani C; Fischer SG; Boeke S; Niyazi M; Thorwarth D; Voigt O; Schneider M; Mönnich D; Kübler S; Boldt J; Hoffmann E; Paulsen F; Mueller AC; Wegener D
    Curr Oncol; 2024 May; 31(5):2679-2688. PubMed ID: 38785484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulated bladder wall dose is correlated with patient-reported acute urinary toxicity in prostate cancer patients treated with stereotactic, daily adaptive MR-guided radiotherapy.
    Willigenburg T; van der Velden JM; Zachiu C; Teunissen FR; Lagendijk JJW; Raaymakers BW; de Boer JCJ; van der Voort van Zyp JRN
    Radiother Oncol; 2022 Jun; 171():182-188. PubMed ID: 35489444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
    Chin JL; Billia M; Relle J; Roethke MC; Popeneciu IV; Kuru TH; Hatiboglu G; Mueller-Wolf MB; Motsch J; Romagnoli C; Kassam Z; Harle CC; Hafron J; Nandalur KR; Chronik BA; Burtnyk M; Schlemmer HP; Pahernik S
    Eur Urol; 2016 Sep; 70(3):447-55. PubMed ID: 26777228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.
    Hsu CC; Hsu H; Pickett B; Crehange G; Hsu IC; Dea R; Weinberg V; Gottschalk AR; Kurhanewicz J; Shinohara K; Roach M
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):370-7. PubMed ID: 22672747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.